|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:bindingSite
|
allosteric site on reverse transcriptase
|
|
gptkbp:category
|
antiretroviral drugs
|
|
gptkbp:compatibleWith
|
phosphorylation for activation
|
|
gptkbp:contraindication
|
gptkb:rifampin
|
|
gptkbp:drugInteraction
|
CYP450 inducers/inhibitors
|
|
gptkbp:example
|
gptkb:delavirdine
gptkb:efavirenz
gptkb:etravirine
gptkb:nevirapine
gptkb:rilpivirine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NNRTIs
|
|
gptkbp:mechanismOfAction
|
inhibit reverse transcriptase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notEffectiveAgainst
|
gptkb:HIV-2
|
|
gptkbp:oftenUsedWith
|
gptkb:NRTIs
protease inhibitors
|
|
gptkbp:pregnancyCategory
|
varies by drug
|
|
gptkbp:resistanceDevelops
|
rapidly if used as monotherapy
|
|
gptkbp:sideEffect
|
rash
hepatotoxicity
CNS effects
|
|
gptkbp:standsFor
|
Non-nucleoside reverse transcriptase inhibitors
|
|
gptkbp:target
|
HIV-1 reverse transcriptase
|
|
gptkbp:usedFor
|
HIV treatment
|
|
gptkbp:WHOStatus
|
gptkb:List_of_Essential_Medicines
|
|
gptkbp:bfsParent
|
gptkb:HIV/AIDS
|
|
gptkbp:bfsLayer
|
4
|